Additionally, the E-MSC-treated ischemia groups showed a substantial reduction in inflammatory cytokine (TNF-α, IL-1β, IL-6, and TGF-β) levels and a notable increase in angiogenetic cytokine (ANG1, FGF, VEGF, and PDGF) levels compared to the control group. The gene discussed is IL1B; the disease is ischemia.